# Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia

> **NCT02654730** · PHASE2,PHASE3 · TERMINATED · sponsor: **London School of Hygiene and Tropical Medicine** · enrollment: 61 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient
- **DRUG:** Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient
- **DRUG:** Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient
- **DRUG:** Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal
- **DRUG:** Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal

## Key facts

- **NCT ID:** NCT02654730
- **Lead sponsor:** London School of Hygiene and Tropical Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-09
- **Final completion:** 2016-12
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Enrollment took longer than anticipated; it was financially and logistically impossible to recruit the final cohort (G6PDd 0.4mg/kg PQ).
- **Last updated:** 2016-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02654730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02654730, "Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia". Retrieved via MORVS 2026-10-12 from https://api.morvs.ai/clinical/NCT02654730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*